EA200800880A1 - Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции - Google Patents

Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции

Info

Publication number
EA200800880A1
EA200800880A1 EA200800880A EA200800880A EA200800880A1 EA 200800880 A1 EA200800880 A1 EA 200800880A1 EA 200800880 A EA200800880 A EA 200800880A EA 200800880 A EA200800880 A EA 200800880A EA 200800880 A1 EA200800880 A1 EA 200800880A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rosiglitazone
pharmaceutically acceptable
acceptable salt
dropseen
intended
Prior art date
Application number
EA200800880A
Other languages
English (en)
Inventor
Аллен Д. Роузес
Джоанн Хифилд
Энн М. Сондерс
Original Assignee
Смитклайн Бичам (Корк) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200800880(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичам (Корк) Лимитед filed Critical Смитклайн Бичам (Корк) Лимитед
Publication of EA200800880A1 publication Critical patent/EA200800880A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Изобретение, в числе прочего, относится к фармацевтической композиции, содержащей как росиглитазон или его фармацевтически приемлемую соль, так и донепезил или его фармацевтически приемлемую соль, которая находит применение при лечении или предотвращении болезни Альцгеймера или других видов деменции, а также легкого ухудшения когнитивной функции. Кроме того, изобретение относится к пероральным лекарственным формам, включающим росиглитазон или его фармацевтически приемлемую соль и донепезил или его фармацевтически приемлемую соль.
EA200800880A 2005-09-22 2006-09-20 Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции EA200800880A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71935305P 2005-09-22 2005-09-22
US72737705P 2005-10-17 2005-10-17
PCT/US2006/036597 WO2007038112A2 (en) 2005-09-22 2006-09-20 Combination of rosiglitazone and donepezil for improvement of cognitive function

Publications (1)

Publication Number Publication Date
EA200800880A1 true EA200800880A1 (ru) 2009-02-27

Family

ID=37876831

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200800880A EA200800880A1 (ru) 2005-09-22 2006-09-20 Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
EA200800879A EA200800879A1 (ru) 2005-09-22 2006-09-20 Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200800879A EA200800879A1 (ru) 2005-09-22 2006-09-20 Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов

Country Status (16)

Country Link
US (2) US20080262047A1 (ru)
EP (2) EP1926488A2 (ru)
JP (2) JP2009508959A (ru)
KR (2) KR20080058413A (ru)
AR (2) AR056527A1 (ru)
AU (2) AU2006295010A1 (ru)
BR (2) BRPI0616192A2 (ru)
CA (2) CA2623210A1 (ru)
CR (2) CR9848A (ru)
EA (2) EA200800880A1 (ru)
IL (2) IL190217A0 (ru)
MA (2) MA29872B1 (ru)
NO (2) NO20081847L (ru)
PE (2) PE20070618A1 (ru)
TW (2) TW200803851A (ru)
WO (2) WO2007038115A2 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US8815508B2 (en) * 2008-08-12 2014-08-26 Zinfandel Pharmaceuticals, Inc. Method of identifying disease risk factors
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
JP5770173B2 (ja) * 2009-06-25 2015-08-26 アルコブラ、リミテッドＡｌｃｏｂｒａ Ｌｔｄ． 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
US20130267560A1 (en) * 2010-10-22 2013-10-10 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
AU2011354696B2 (en) * 2011-01-10 2015-03-05 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EA201691399A1 (ru) 2011-01-10 2016-10-31 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
CA2852417A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
CA2853100A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
EP3490551A2 (en) * 2016-07-26 2019-06-05 Ausio Pharmaceuticals, LLC Methods of diagnosing and treating alzheimer's disease with s-equol
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262592T1 (de) * 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AU2192000A (en) * 1998-12-17 2000-07-03 Mindset Biopharmaceuticals (Usa) Inc. Increasing brain glucose utilization
EP1718294A4 (en) * 2004-01-30 2007-10-03 Axonyx Inc METHODS OF TREATING COMPLICATIONS OF DIABETES

Also Published As

Publication number Publication date
EA200800879A1 (ru) 2008-10-30
PE20070618A1 (es) 2007-07-04
WO2007038115A3 (en) 2007-12-13
NO20081847L (no) 2008-06-18
BRPI0616192A2 (pt) 2011-06-14
WO2007038112A2 (en) 2007-04-05
AR055649A1 (es) 2007-08-29
MA29871B1 (fr) 2008-10-03
CR9849A (es) 2008-05-21
BRPI0616100A2 (pt) 2011-06-07
WO2007038112A3 (en) 2007-12-06
IL190224A0 (en) 2008-11-03
TW200803896A (en) 2008-01-16
AU2006295007A1 (en) 2007-04-05
IL190217A0 (en) 2008-11-03
JP2009508960A (ja) 2009-03-05
WO2007038115A2 (en) 2007-04-05
CA2623204A1 (en) 2007-04-05
US20080226719A1 (en) 2008-09-18
MA29872B1 (fr) 2008-10-03
KR20080056731A (ko) 2008-06-23
KR20080058413A (ko) 2008-06-25
JP2009508959A (ja) 2009-03-05
CR9848A (es) 2008-06-18
EP1926488A2 (en) 2008-06-04
PE20070976A1 (es) 2007-12-05
US20080262047A1 (en) 2008-10-23
NO20081843L (no) 2008-06-16
TW200803851A (en) 2008-01-16
AU2006295010A1 (en) 2007-04-05
EP1940403A2 (en) 2008-07-09
AR056527A1 (es) 2007-10-10
CA2623210A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
EA200401114A2 (ru) Замещённые гидроксиэтиламины
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
ATE458753T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
GB0223040D0 (en) Therapeutic compounds
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
EA200400881A1 (ru) Азаарилпиперазины
SE0104341D0 (sv) New use
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
EA200600866A1 (ru) Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60322577D1 (de) Tablette enthaltend efletirizin und pseudoephedrin
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
ATA8192003A (de) Verwendung von oxicam-verbindungen